MasterCard Inc vs Summit Therapeutics Inc — how do they compare? MasterCard Inc trades at $559.84 (market cap $491.83B), while Summit Therapeutics Inc trades at $15.23 (market cap $12.06B). The key difference: MasterCard Inc is far larger — about 40.8× Summit Therapeutics Inc's market cap, and MasterCard Inc pays a 0.62% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MA | SMMT | |
|---|---|---|
Market Cap | $491.83B | $12.06B |
Volume | 4,635,698 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $598.96 | $26.98 |
52-Week Low | $471.55 | $12.55 |
Enterprise Value | $504.86B | $11.39B |
Dividend Yield | 0.62% | — |
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $557.09, down 1.08% today, but maintains strong bullish technical momentum with consistent earnings beats and robust financial performance. The company reported Q2 2026 EPS of $5.04, beating expectations of $4.77, continuing a pattern of strong quarterly results. Revenue growth remains solid with 2025 revenue reaching $32.79 billion and net income of $14.97 billion, demonstrating the company's dominant position in payment processing. Recent institutional buying activity and positive analyst sentiment support the stock's upward trajectory.
Mastercard presents a compelling investment opportunity with strong fundamentals, consistent earnings growth, and bullish analyst consensus. The stock offers 18.6% upside to the consensus price target of $660.85. Key risks include competitive threats from emerging payment technologies and potential regulatory challenges in the financial services sector. The company's aggressive AI investments and global expansion initiatives position it well for continued growth, though investors should monitor payment industry disruption from stablecoins and digital payment innovations.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Trailing returns across standard periods
Latest headlines on both assets
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →